北大医药股份有限公司关于公司以公开竞拍方式购买股权暨关联交易的进展公告

Group 1 - The company has approved the acquisition of a 9.75% stake in Chongqing Daxin Pharmaceutical Co., Ltd. through a public auction, which constitutes a related party transaction [2][3][52] - The acquisition was successfully completed at a price of 22 million yuan [3] - This transaction aims to reduce reliance on leasing arrangements and enhance the stability of the company's production system [4][53] Group 2 - The company plans to apply for a total bank credit limit of 800 million yuan for 2026, providing guarantees for its wholly-owned subsidiaries [8][9] - The total guarantee amount for the subsidiaries is expected to be no more than 300 million yuan [9][16] - The board of directors has approved the financing plan, which is intended to alleviate financial pressure and lower financing costs [15][20] Group 3 - The company estimates that its daily related party transactions with Chongqing Southwest Synthetic Pharmaceutical Co., Ltd. for 2026 will not exceed 16.01 million yuan [23][39] - The company also anticipates related party transactions with China Ping An Insurance (Group) Co., Ltd. and other related parties to total no more than 57.63 million yuan [27][39] - These transactions are essential for the company's daily operations and are expected to be conducted at fair market prices [41][40] Group 4 - The company has a strategic plan to deepen its involvement in the raw material pharmaceutical industry, aiming to optimize overall profitability and achieve synergy within the industry chain [4][53][63] - The acquisition of the stake in Daxin Pharmaceutical is part of this strategy, allowing the company to directly benefit from the industry's growth [4][53] - Daxin Pharmaceutical is recognized as a key high-tech enterprise with strong production capabilities and a comprehensive quality system [63]